Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023
10 Julho 2023 - 8:30AM
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative
medicine company focused on the development, manufacture, and
commercialization of product solutions for the Advanced Wound Care
and Surgical & Sports Medicine markets, today announced that
second quarter of fiscal year 2023 financial results will be
reported after the market closes on Wednesday, August 9th.
Management will host a conference call at 5:00
p.m. Eastern Time on August 9th to discuss the results of the
quarter and provide a corporate update with a question and answer
session. Those who would like to participate may access the live
webcast here, or access the teleconference here. The live webcast
can also be accessed via the company’s website at
investors.organogenesis.com. The webcast will be archived on the
company website for approximately one year.
About Organogenesis Holdings
Inc. Organogenesis Holdings Inc. is a leading regenerative
medicine company offering a portfolio of bioactive and acellular
biomaterials products in advanced wound care and surgical
biologics, including orthopedics and spine. Organogenesis’s
comprehensive portfolio is designed to treat a variety of patients
with repair and regenerative needs. For more information, visit
www.organogenesis.com.
Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
OrganoIR@westwicke.com
Press and Media Inquiries:
Organogenesis
Ron O’Brien
communications@organo.com
Organogenesis (NASDAQ:ORGO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Organogenesis (NASDAQ:ORGO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024